(USNA) USANA Health Sciences - Overview
Stock: Vitamins, Supplements, Skincare, Meal Shakes, Snack Bars
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 40.1% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.66 |
| Alpha | -45.71 |
| Character TTM | |
|---|---|
| Beta | 0.813 |
| Beta Downside | 0.926 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.51% |
| CAGR/Max DD | -0.41 |
Description: USNA USANA Health Sciences December 26, 2025
USANA Health Sciences (NYSE:USNA) designs, manufactures, and markets science-based nutritional, personal-care, and skincare products across the Asia-Pacific, Americas, and Europe, operating through a Direct-Selling segment and a Hiya Direct-to-Consumer (DTC) segment.
Its core portfolio includes USANA Optimizers (cardiovascular, skeletal, and digestive health), Essentials/CellSentials (vitamins and minerals for children 13 months onward), and food items such as meal-replacement shakes and snack bars. The company also sells Celavive skincare, and provides online tools and materials to support its independent associate network. Sales channels combine retail, subscription, direct-selling, and e-commerce platforms.
Recent performance shows FY2023 revenue of roughly $2.5 billion, with the Direct-Selling segment contributing about 70 % of total sales and a 5 % year-over-year growth in DTC subscriptions-reflecting broader consumer shifts toward online health-product purchasing. Key economic drivers include rising global demand for preventive health supplements, an aging demographic in core markets, and expanding middle-class consumption in Asia-Pacific. USANA’s research partnership with Beijing University of Chinese Medicine and the National Sports Training Bureau underscores its focus on product innovation and credibility.
For a deeper quantitative assessment of USANA’s valuation dynamics, you may find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 17.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -7.20 > 1.0 |
| NWC/Revenue: 15.93% < 20% (prev 39.03%; Δ -23.10% < -1%) |
| CFO/TA 0.04 > 3% & CFO 31.5m > Net Income 17.0m |
| Net Debt (-145.3m) to EBITDA (83.9m): -1.73 < 3 |
| Current Ratio: 2.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.3m) vs 12m ago -4.14% < -2% |
| Gross Margin: 76.11% > 18% (prev 0.79%; Δ 7532 % > 0.5%) |
| Asset Turnover: 130.6% > 50% (prev 128.4%; Δ 2.18% > 0%) |
| Interest Coverage Ratio: 57.34 > 6 (EBITDA TTM 83.9m / Interest Expense TTM 848.0k) |
Altman Z'' 7.12
| A: 0.20 (Total Current Assets 264.1m - Total Current Liabilities 118.7m) / Total Assets 726.6m |
| B: 0.64 (Retained Earnings 467.5m / Total Assets 726.6m) |
| C: 0.07 (EBIT TTM 48.6m / Avg Total Assets 698.9m) |
| D: 3.09 (Book Value of Equity 448.2m / Total Liabilities 145.0m) |
| Altman-Z'' Score: 7.12 = AAA |
Beneish M -1.85
| DSRI: 1.08 (Receivables 8.22m/7.20m, Revenue 912.7m/862.0m) |
| GMI: 1.04 (GM 76.11% / 79.30%) |
| AQI: 2.77 (AQ_t 0.50 / AQ_t-1 0.18) |
| SGI: 1.06 (Revenue 912.7m / 862.0m) |
| TATA: -0.02 (NI 17.0m - CFO 31.5m) / TA 726.6m) |
| Beneish M-Score: -1.85 (Cap -4..+1) = B |
What is the price of USNA shares?
Over the past week, the price has changed by -1.48%, over one month by +6.65%, over three months by +11.26% and over the past year by -31.23%.
Is USNA a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the USNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39 | 82.8% |
| Analysts Target Price | 39 | 82.8% |
| ValueRay Target Price | 17.1 | -19.9% |
USNA Fundamental Data Overview February 09, 2026
P/E Forward = 8.2102
P/S = 0.4274
P/B = 0.7387
P/EG = 0.684
Revenue TTM = 912.7m USD
EBIT TTM = 48.6m USD
EBITDA TTM = 83.9m USD
Long Term Debt = 6.01m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 29.0m USD (from shortTermDebt, last fiscal year)
Debt = 39.2m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -145.3m USD (from netDebt column, last quarter)
Enterprise Value = 284.0m USD (390.1m + Debt 39.2m - CCE 145.3m)
Interest Coverage Ratio = 57.34 (Ebit TTM 48.6m / Interest Expense TTM 848.0k)
EV/FCF = 15.19x (Enterprise Value 284.0m / FCF TTM 18.7m)
FCF Yield = 6.58% (FCF TTM 18.7m / Enterprise Value 284.0m)
FCF Margin = 2.05% (FCF TTM 18.7m / Revenue TTM 912.7m)
Net Margin = 1.86% (Net Income TTM 17.0m / Revenue TTM 912.7m)
Gross Margin = 76.11% ((Revenue TTM 912.7m - Cost of Revenue TTM 218.0m) / Revenue TTM)
Gross Margin QoQ = 73.45% (prev 75.44%)
Tobins Q-Ratio = 0.39 (Enterprise Value 284.0m / Total Assets 726.6m)
Interest Expense / Debt = 0.12% (Interest Expense 49.0k / Debt 39.2m)
Taxrate = 44.91% (34.3m / 76.4m)
NOPAT = 26.8m (EBIT 48.6m * (1 - 44.91%))
Current Ratio = 2.23 (Total Current Assets 264.1m / Total Current Liabilities 118.7m)
Debt / Equity = 0.07 (Debt 39.2m / totalStockholderEquity, last quarter 528.1m)
Debt / EBITDA = -1.73 (Net Debt -145.3m / EBITDA 83.9m)
Debt / FCF = -7.78 (Net Debt -145.3m / FCF TTM 18.7m)
Total Stockholder Equity = 530.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.43% (Net Income 17.0m / Total Assets 726.6m)
RoE = 3.21% (Net Income TTM 17.0m / Total Stockholder Equity 530.3m)
RoCE = 9.07% (EBIT 48.6m / Capital Employed (Equity 530.3m + L.T.Debt 6.01m))
RoIC = 4.94% (NOPAT 26.8m / Invested Capital 541.8m)
WACC = 8.10% (E(390.1m)/V(429.3m) * Re(8.91%) + D(39.2m)/V(429.3m) * Rd(0.12%) * (1-Tc(0.45)))
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.52%
[DCF Debug] Terminal Value 75.45% ; FCFF base≈37.5m ; Y1≈32.6m ; Y5≈26.0m
Fair Price DCF = 33.23 (EV 462.2m - Net Debt -145.3m = Equity 607.5m / Shares 18.3m; r=8.10% [WACC]; 5y FCF grow -16.00% → 2.90% )
EPS Correlation: -70.27 | EPS CAGR: -29.21% | SUE: -1.02 | # QB: 0
Revenue Correlation: -64.29 | Revenue CAGR: -5.80% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.40 | Chg30d=-0.040 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.95 | Chg30d=-0.150 | Revisions Net=-1 | Growth EPS=+12.1% | Growth Revenue=+3.4%